Nippon Chemiphar Co., Ltd. (TYO:4539)

Japan · Delayed Price · Currency is JPY

1,550.00

+2.00 (0.13%)

Sep 14, 2026, 3:24 PM JST

Market Cap	5.61B -3.6%
Revenue (ttm)	33.02B +0.6%
Net Income	-124.00M
EPS	-34.28
Shares Out	3.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	50.00 (3.16%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,200
Open	1,553.00
Previous Close	1,548.00
Day's Range	1,545.00 - 1,553.00
52-Week Range	1,502.00 - 1,857.00
Beta	0.18
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Nippon Chemiphar

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment o... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1950

Employees 878

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4539

Full Company Profile

Financial Performance

In fiscal year 2026, Nippon Chemiphar's revenue was 33.09 billion, an increase of 1.60% compared to the previous year's 32.57 billion. Earnings were 198.00 million, a decrease of -32.65%.

Financial Statements